CN116635393A - 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 - Google Patents

中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 Download PDF

Info

Publication number
CN116635393A
CN116635393A CN202180074185.9A CN202180074185A CN116635393A CN 116635393 A CN116635393 A CN 116635393A CN 202180074185 A CN202180074185 A CN 202180074185A CN 116635393 A CN116635393 A CN 116635393A
Authority
CN
China
Prior art keywords
alkyl
compound
alkenyl
certain embodiments
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180074185.9A
Other languages
English (en)
Chinese (zh)
Inventor
B·莱夫克
G·萨克斯蒂
K·吉布森
M·匹克沃思
M·斯彭迪夫
M·康格里夫
P·汉弗莱斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sentesa Pharmaceuticals Uk Ltd
Original Assignee
Ouruixia Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ouruixia Treatment Co ltd filed Critical Ouruixia Treatment Co ltd
Publication of CN116635393A publication Critical patent/CN116635393A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202180074185.9A 2020-09-03 2021-09-03 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 Pending CN116635393A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063074220P 2020-09-03 2020-09-03
US63/074220 2020-09-03
PCT/US2021/049003 WO2022051583A1 (en) 2020-09-03 2021-09-03 Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists

Publications (1)

Publication Number Publication Date
CN116635393A true CN116635393A (zh) 2023-08-22

Family

ID=78078371

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180074185.9A Pending CN116635393A (zh) 2020-09-03 2021-09-03 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途

Country Status (6)

Country Link
US (1) US20230331720A1 (cg-RX-API-DMAC7.html)
EP (1) EP4208465A1 (cg-RX-API-DMAC7.html)
JP (1) JP7811578B2 (cg-RX-API-DMAC7.html)
CN (1) CN116635393A (cg-RX-API-DMAC7.html)
TW (1) TW202227433A (cg-RX-API-DMAC7.html)
WO (1) WO2022051583A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
JP7833486B2 (ja) * 2021-05-26 2026-03-19 アルカーメス,インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
WO2023167925A1 (en) * 2022-03-01 2023-09-07 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses
US20260116891A1 (en) * 2022-04-22 2026-04-30 Teijin Pharma Limited Oxazepin Derivative
CN114716319B (zh) * 2022-04-28 2024-03-26 浙江工业大学 一种联芳氧基烯酸酯类化合物的合成方法
EP4600242A1 (en) * 2022-10-07 2025-08-13 Kissei Pharmaceutical Co., Ltd. Cyclopentane compound
TW202432109A (zh) 2022-10-31 2024-08-16 日商武田藥品工業股份有限公司 食慾素2型受體促效劑之給藥
EP4680611A1 (en) 2023-03-16 2026-01-21 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
JP2026518313A (ja) 2023-06-01 2026-06-04 ハー・ルンドベック・アクチエゼルスカベット スピロ大環状オレキシン2受容体アゴニスト
TW202502342A (zh) 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素2受體促效劑用於改善睡眠期間之呼吸功能的用途
UY40937A (es) * 2023-10-20 2025-04-30 Teijin Pharma Ltd Cristal de derivado de oxazepina o cristal de solvato del mismo
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
US20260144795A1 (en) 2024-11-27 2026-05-28 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101880276A (zh) * 2006-12-01 2010-11-10 默沙东公司 作为食欲素受体拮抗剂的取代的二氮杂环庚烷化合物
CN111051295A (zh) * 2017-08-03 2020-04-21 武田药品工业株式会社 杂环化合物及其用途
WO2020158958A1 (en) * 2019-01-31 2020-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
KR20260083444A (ko) * 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101880276A (zh) * 2006-12-01 2010-11-10 默沙东公司 作为食欲素受体拮抗剂的取代的二氮杂环庚烷化合物
CN111051295A (zh) * 2017-08-03 2020-04-21 武田药品工业株式会社 杂环化合物及其用途
WO2020158958A1 (en) * 2019-01-31 2020-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
杨妙;邓康;: "食欲素受体拮抗剂的研究进展", 天津药学, no. 05, 28 October 2017 (2017-10-28), pages 69 - 73 *

Also Published As

Publication number Publication date
WO2022051583A1 (en) 2022-03-10
EP4208465A1 (en) 2023-07-12
JP2023540350A (ja) 2023-09-22
JP7811578B2 (ja) 2026-02-05
TW202227433A (zh) 2022-07-16
US20230331720A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
US12503475B2 (en) Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン-2受容体アゴニストとしてのそれらの使用
ES3041424T3 (en) Substituted macrocyclic compounds and related methods of treatment
AU2024350399A1 (en) Ras-pi3k inhibitors for the treatment of cancer and immunological diseases
TWI915407B (zh) Apol1抑制劑及其使用方法
IL322853A (en) History of 1-(([1,1'-biphenyl]-2-yl)sulfonyl)-4-fluoro-n-(3-(methylsulfonyl)allyl)piperidine-4-carboxamide as ras-pi3k modulators for exemplary cancer therapy
CN103097364B (zh) 作为s1p调节剂的螺-哌啶衍生物
CN119110802A (zh) 中环或大环苄基取代的杂环衍生物和相关用途
TW201920115A (zh) 化合物、組合物及方法
CN111699180A (zh) 作为lpa拮抗剂的吡唑n-连接的氨基甲酰基环己基酸
CN114599648A (zh) 作为lpa拮抗剂的三唑羧酸
CN119156375A (zh) 双环杂环衍生物和相关用途
WO2019179515A1 (zh) 受体抑制剂、包含其的药物组合物及其用途
TW202515851A (zh) Keap1抑制劑及其用途
CN114761383A (zh) 磺酰胺衍生物及其用途
KR102865307B1 (ko) 수용체 억제제, 이를 포함하는 약학적 조성물 및 그 용도
CN107922426B (zh) 四氢噁庚英吡啶化合物
EA052303B1 (ru) Средне- или макроциклические производные бензилзамещенного гетероцикла и связанные с ними применения
HK40111671A (en) Ferroptosis modulators, preparations, and uses thereof
HK40032239A (en) Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof
HK40029777A (en) Receptor inhibitor, pharmaceutical composition comprising same, and use thereof
HK1184153B (en) Spiro-cyclic amine derivatives as s1p modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Cheshire

Applicant after: Sentesa Pharmaceuticals (Oresa) Co.,Ltd.

Address before: London

Applicant before: Ouruixia Treatment Co.,Ltd.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240218

Address after: Cheshire

Applicant after: Sentesa Pharmaceuticals (UK) Ltd.

Country or region after: United Kingdom

Address before: Cheshire

Applicant before: Sentesa Pharmaceuticals (Oresa) Co.,Ltd.

Country or region before: United Kingdom